Strategic Partners A/S
Finance·STRAP · Nasdaq Copenhagen·Fiscal year to 31/12/2025
Strategic partnerships and active ownership in companies. Formerly Orphazyme.
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Equity and capital markets
Macro
StrategyPositive impact: strengthens
“As part of the strategy - and to constantly grow the company's balance sheet - capital is being sought continuously via capital increases/share issues.”
Annual report 2025A · The company itself
M&A and consolidation
Macro
Market
“In January 2025 the Company sold the position in CombiGene AB for a price close to the acquisition cost and in October 2025 the Company acquired 10% of the investment company Avium Fund I ApS.”
Annual report 2025A · The company itself
Other currencies
Macro
DriverNegative impact: weakens
“The Company has currently only identified currency risks as relevant for the Company due to the limited ongoing business operations of Strategic Partners A/S. Financial risks may arise from changes in exchange rates and changes in stock prices. The Company are mostly exposed to foreign exchange movements relating to USD and EUR.”
Annual report 2025A · The company itself
USD vs DKK/EUR
Macro
DriverNegative impact: weakens
“The Company has currently only identified currency risks as relevant for the Company due to the limited ongoing business operations of Strategic Partners A/S. Financial risks may arise from changes in exchange rates and changes in stock prices. The Company are mostly exposed to foreign exchange movements relating to USD and EUR.”
Annual report 2025A · The company itself
Chains out: this mixed effect United States
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | N/A |
| Revenue growth vs. the year before, same method | N/A |
| EBITDA reported by the company | N/A |
| Net debt debt incl. leasing minus cash | N/A |
| Diluted EPS per share | -49 DKK |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✗ |
| Growing | N/A |
| Healthy balance sheet | ✓ |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.